WO2007124698A3 - Métodos para tratar la infección por flavivirus, moléculas y usos - Google Patents

Métodos para tratar la infección por flavivirus, moléculas y usos Download PDF

Info

Publication number
WO2007124698A3
WO2007124698A3 PCT/CU2007/000014 CU2007000014W WO2007124698A3 WO 2007124698 A3 WO2007124698 A3 WO 2007124698A3 CU 2007000014 W CU2007000014 W CU 2007000014W WO 2007124698 A3 WO2007124698 A3 WO 2007124698A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
treatment
methods
receptor
flavivirus infection
Prior art date
Application number
PCT/CU2007/000014
Other languages
English (en)
French (fr)
Other versions
WO2007124698A2 (es
Inventor
Galindo Vivian Huerta
Santiago Glay Chinea
Salazar Noralvis Fleitas
Dunn Alejandro Miguel Martin
Nunez Monica Sarria
Cruz Osmany Guirola
Mayora Patricia Gabriel Toledo
Puente Aniel Sanchez
Perez Vladimir Armando Besada
Acosta Osvaldo Reyes
Perez Hilda Elisa Garay
Rico Ania Cabrales
Lasa Alexis Musacchio
Palomares Gabriel Ramon Padron
Lopez Luis Javier Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Galindo Vivian Huerta
Santiago Glay Chinea
Salazar Noralvis Fleitas
Dunn Alejandro Miguel Martin
Nunez Monica Sarria
Cruz Osmany Guirola
Mayora Patricia Gabriel Toledo
Puente Aniel Sanchez
Perez Vladimir Armando Besada
Acosta Osvaldo Reyes
Perez Hilda Elisa Garay
Rico Ania Cabrales
Lasa Alexis Musacchio
Palomares Gabriel Ramon Padron
Lopez Luis Javier Gonzalez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Galindo Vivian Huerta, Santiago Glay Chinea, Salazar Noralvis Fleitas, Dunn Alejandro Miguel Martin, Nunez Monica Sarria, Cruz Osmany Guirola, Mayora Patricia Gabriel Toledo, Puente Aniel Sanchez, Perez Vladimir Armando Besada, Acosta Osvaldo Reyes, Perez Hilda Elisa Garay, Rico Ania Cabrales, Lasa Alexis Musacchio, Palomares Gabriel Ramon Padron, Lopez Luis Javier Gonzalez filed Critical Ct Ingenieria Genetica Biotech
Priority to EP07721810.5A priority Critical patent/EP2022506B1/en
Priority to ES07721810.5T priority patent/ES2645679T3/es
Priority to CA2650591A priority patent/CA2650591C/en
Priority to CN2007800224852A priority patent/CN101472606B/zh
Priority to AU2007246076A priority patent/AU2007246076B2/en
Priority to US12/298,808 priority patent/US8420311B2/en
Publication of WO2007124698A2 publication Critical patent/WO2007124698A2/es
Publication of WO2007124698A3 publication Critical patent/WO2007124698A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un método para bloquear la infección del virus dengue a las células que comprende la interferencia en la interacción de la proteína de la envoltura del virus con un receptor celular directamente o a través de una proteína portadora y los usos relacionados, siendo el receptor celular el receptor de la alfa2-macroglobulina también conocido como proteína relacionada al receptor de lipoproteínas de baja densidad o CD91 y siendo la proteína portadora la alfa 2-macroglobulina humana.
PCT/CU2007/000014 2006-04-28 2007-04-26 Métodos para tratar la infección por flavivirus, moléculas y usos WO2007124698A2 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP07721810.5A EP2022506B1 (en) 2006-04-28 2007-04-26 Method for the treatment of flavivirus infection, molecules and uses thereof
ES07721810.5T ES2645679T3 (es) 2006-04-28 2007-04-26 Método para el tratamiento de infección por flavivirus, moléculas y sus usos
CA2650591A CA2650591C (en) 2006-04-28 2007-04-26 Methods for the treatment of flavivirus infection, molecules and uses thereof
CN2007800224852A CN101472606B (zh) 2006-04-28 2007-04-26 用于治疗黄病毒感染的方法、分子及用途
AU2007246076A AU2007246076B2 (en) 2006-04-28 2007-04-26 Methods for the treatment of flavivirus infection, molecules and uses thereof
US12/298,808 US8420311B2 (en) 2006-04-28 2007-04-26 Method to block the infection by flaviviruses, molecules and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060091A CU23632A1 (es) 2006-04-28 2006-04-28 Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
CU2006-0091 2006-04-28

Publications (2)

Publication Number Publication Date
WO2007124698A2 WO2007124698A2 (es) 2007-11-08
WO2007124698A3 true WO2007124698A3 (es) 2007-12-27

Family

ID=38476089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2007/000014 WO2007124698A2 (es) 2006-04-28 2007-04-26 Métodos para tratar la infección por flavivirus, moléculas y usos

Country Status (11)

Country Link
US (1) US8420311B2 (es)
EP (1) EP2022506B1 (es)
CN (1) CN101472606B (es)
AR (1) AR060827A1 (es)
AU (1) AU2007246076B2 (es)
CA (1) CA2650591C (es)
CU (1) CU23632A1 (es)
ES (1) ES2645679T3 (es)
MY (1) MY150685A (es)
RU (1) RU2008146997A (es)
WO (1) WO2007124698A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2013126587A1 (en) 2012-02-21 2013-08-29 Cytonics Corporation Systems, compositions, and methods for transplantation
AU2013299986B2 (en) * 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
US10442868B2 (en) 2013-03-14 2019-10-15 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis B virus infections by administering receptor associated protein (RAP)
SG11201606624WA (en) 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
CA2938495A1 (en) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
CN111537316A (zh) * 2020-06-17 2020-08-14 陕西健吉跃生物科技有限公司 一种检测蛋白含量的氨基黑染色液、试剂盒及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
US6403092B1 (en) 1998-04-01 2002-06-11 Duke University Immune response modulator alpha-2 macroglobulin complex
US7449321B2 (en) * 2003-01-22 2008-11-11 National University Of Singapore Molecules, compositions, methods and kits for applications associated with flaviviruses
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
WO2005123774A2 (en) * 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
DE102006014892B4 (de) 2005-03-31 2020-09-24 Ngk Spark Plug Co., Ltd. Gassensorelement, Verfahren zu seiner Herstellung, und Gassensor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CABRERA-HERNANDEZ A ET AL: "Mammalian dengue virus receptors", DENGUE BULLETIN 2005 INDIA, vol. 29, 2005, pages 119 - 135, XP001536276, ISSN: 1020-895X *
DATABASE Geneseq [online] 20 May 2004 (2004-05-20), "Envelope protein domain III, SEQ ID 8.", XP002453500, retrieved from EBI accession no. GSP:ADK13688 Database accession no. ADK13688 *
DATABASE Geneseq [online] 3 September 1992 (1992-09-03), "DEN1 E glycoprotein (373-398).", XP002453499, retrieved from EBI accession no. GSP:AAR25390 Database accession no. AAR25390 *
DATABASE Geneseq [online] 9 March 2006 (2006-03-09), "West Nile virus envelope protein ectodomain peptide 39.", XP002453298, retrieved from EBI accession no. GSP:AEF13619 Database accession no. AEF13619 *
KOFF W C ET AL: "INHIBITION OF DENGUE VIRUS REPLICATION BY AMANTADINE HYDRO CHLORIDE", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 18, no. 1, July 1980 (1980-07-01), pages 125 - 129, XP009089666, ISSN: 0066-4804 *
SCHLEGEL R ET AL: "AMANTADINE AND DANSYL CADAVERINE INHIBIT VESICULAR STOMATITIS VIRUS UPTAKE AND RECEPTOR MEDIATED ENDOCYTOSIS OF ALPHA-2 MACRO GLOBULIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 79, no. 7, 1982, pages 2291 - 2295, XP002453279, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CU23632A1 (es) 2011-02-24
US20110212105A1 (en) 2011-09-01
CN101472606B (zh) 2012-09-19
CA2650591C (en) 2014-10-07
AR060827A1 (es) 2008-07-16
RU2008146997A (ru) 2010-06-10
CA2650591A1 (en) 2007-11-08
US8420311B2 (en) 2013-04-16
EP2022506B1 (en) 2017-10-11
WO2007124698A2 (es) 2007-11-08
EP2022506A2 (en) 2009-02-11
CN101472606A (zh) 2009-07-01
ES2645679T3 (es) 2017-12-07
MY150685A (en) 2014-02-28
AU2007246076B2 (en) 2011-06-23
AU2007246076A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007124698A3 (es) Métodos para tratar la infección por flavivirus, moléculas y usos
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
WO2010043650A3 (en) Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry
WO2006074346A3 (en) RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF
WO2007081974A3 (en) Viral hepatitis treatment
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
DK1755634T3 (da) Oligopeptider til formindskelse af forhöjet blodurinstofkoncentration
WO2009120365A3 (en) Methods and compositions for the delivery of agents
WO2008016664A3 (en) Compositions and methods for treating cancer with dacarbazine nanoemulsions
MX2009003542A (es) Metodos y composiciones con opalescencia reducida.
EP2628746A3 (en) A process for concentration of a polypeptide
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
WO2007021672A3 (en) Vaccination against dengue virus infection
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
EP2177531A3 (en) Cell permeable peptide
PT2046373E (pt) Oxalato descarboxilase cristalizada e métodos de utilização
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2010056898A3 (en) Rapid expression cloning of human monoclonal antibodies from memory b cells
WO2010047830A3 (en) Agents for hcv treatment
WO2007062174A3 (en) Devices and methods for high-pressure refolding of proteins
BRPI0912230A2 (pt) Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780022485.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07721810

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2650591

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6233/CHENP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007246076

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2007721810

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008146997

Country of ref document: RU

Ref document number: 2007721810

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007246076

Country of ref document: AU

Date of ref document: 20070426

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12298808

Country of ref document: US